Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables: 2013-2025

Historic Receivables for Coherus Oncology (CHRS) over the last 9 years, with Sep 2025 value amounting to $250.5 million.

  • Coherus Oncology's Receivables rose 26.00% to $250.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $554.9 million, marking a year-over-year decrease of 47.50%. This contributed to the annual value of $122.3 million for FY2024, which is 53.04% down from last year.
  • Coherus Oncology's Receivables amounted to $250.5 million in Q3 2025, which was up 109.38% from $119.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Receivables ranged from a high of $313.6 million in Q2 2024 and a low of $62.4 million during Q1 2025.
  • Over the past 3 years, Coherus Oncology's median Receivables value was $198.8 million (recorded in 2024), while the average stood at $188.3 million.
  • As far as peak fluctuations go, Coherus Oncology's Receivables soared by 180.07% in 2024, and later slumped by 78.03% in 2025.
  • Coherus Oncology's Receivables (Quarterly) stood at $123.0 million in 2021, then dropped by 10.61% to $110.0 million in 2022, then spiked by 136.92% to $260.5 million in 2023, then crashed by 53.04% to $122.3 million in 2024, then rose by 26.00% to $250.5 million in 2025.
  • Its Receivables stands at $250.5 million for Q3 2025, versus $119.6 million for Q2 2025 and $62.4 million for Q1 2025.